Версия сайта для людей с нарушением зрения
    шрифт
только для медицинских специалистов

Консультант врача

Электронная медицинская библиотека

Обычная версия
Раздел 11 / 21
Страница 1 / 1

Список литературы

  1. Каган М.Ю. Гемолитико-уремический синдром, ассоциированный с пневмококковой инфекцией (Обзор литературы) Нефрология и диализ, 2013 год; 15(2): 116-119
  2. Луара Ш. Гемолитико-уремический синдром. В кн: Детская нефрология. Практическое руководство. Под ред. Э.Лойманна, А.Н.Цыгина и А.А.Саркисяна.- М.:Литтерра, 2010.-400 с.
  3. Резолюция экспертного совета по оптимизации подходов к терапии атипичного гемолитико-уремического синдрома по итогам заседания 18 апреля 2014 года, г. Москва Нефрология и диализ, 2014 год; 16(2): 304-306
  4. Шпикалова И.Ю. Панкратенко Т.Е. Эмирова Х.М. Зверев Д.В. Толстова Е.М. Поражение ЦНС у больных с Шига-токсин ассоциированным гемолитико- уремическим синдромом (STEC-ГУС): современные аспекты патогенеза, клиники и стратегии лечения (Обзор литературы) Нефрология и диализ, 2014 ; 16(3): 328-338
  5. Ariceta G, Arrizabalaga B, Aguirre M, Morteruel E, Lopez-Trascasa M. Eculizumab in the treatment of atypical hemolytic uremic syndrome in infants. Am J Kidney Dis. 2012;59:707–10.
  6. Ariceta G, Besbas N, Johnson S, Karpman D et al.. Guideline for the investigation and initial therapy of diarrhea-negative haemolytic uremic syndrome. Pediatr Nephrol 2009 ; 24 : 687-696.
  7. Bresin E, Daina E, Noris M, Castelletti F, Stefanov R, Hill P, Goodship TH, Remuzzi G. Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. Clin J Am Soc Nephrol. 2006;1:88–99
  8. Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, Mele C, Bresin E, Cassis L, Gamba S, Porrati F, Bucchioni S, Monteferrante G, Fang CJ, Liszewski MK, Kavanagh D, Atkinson JP, Remuzzi G. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006;108:1267–79.
  9. Copelovitch L, Kaplan BS. Streptococcus pneumoniae-associated haemolytic uremic syndrome. Pediatr Nephrol 2008 ; 23 : 1951-6.
  10. Davin JC, Strain L, Goodship TH. Plasma therapy in atypical haemolytic uremic syndrome: lessons from a family with a factor H mutation. Pediatr Nephrol. 2008;23:1517–21.
  11. Dragon-Durey MA, Loirat C, Cloarec S, Macher MA, Blouin J, Nivet H, Weiss L, Fridman WH, Fremeaux-Bacchi V. Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2005;16:555–63.
  12. Fakhouri F, Frémeaux-Bacchi V, Loirat C. Atypical hemolytic uremic syndrome: From the rediscovery of complement to targeted therapy. Eur J Intern Med. 2013;24:492–5.
  13. Geraghty MT, Perlman EJ, Martin LS, Hayflick SJ, Casella JF, Rosenblatt DS, Valle D. Cobalamin C defect associated with hemolytic-uremic syndrome. J Pediatr. 1992;120:934–7
  14. Krid S, Roumenina LT, Beury D, Charbit M, Boyer O, Frémeaux-Bacchi V, Niaudet P. Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH/CFHR1 hybrid protein. Am J Transplant. 2012;12:1938–44.
  15. Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368:2169–81.
  16. Loirat C, Fakhouri F, Ariceta G, Besbas N et al. An international consensus approach to the management of atypical haemolytic uremic syndrome in children. Pediatr Nephrol 2015; Published online: 11 April 2015.
  17. Loirat C, Noris M, Fremeaux-Bacchi V. Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol 2008 ; 23 : 1957-72.
  18. Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, van der Meer I, Conway EM, Zipfel PF, Goodship TH, Remuzzi G. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5:1844–59
  19. Noris M, Remuzzi G. Atypical-hemolytic uremic syndrome. N Engl J Med. 2009;361:1676–87.
  20. Noris M, Remuzzi G. Hemolytic uremic syndrome. J Am Soc Nephrol. 2005;16:1035–50
  21. Oakes RS, Kirkham JK, Nelson RD, Siegler RL. Duration of oliguria and anuria as predictors of chronic renal-related sequelae in post-diarrheal haemolytic uremic syndrome. Pediatr Nephrol 2008 ; 23 : 1303-8.
  22. Saland JM, Emre SH, Shneider BL, Benchimol C, Ames S, Bromberg JS, Remuzzi G, Strain L, Goodship TH. Favorable long-term outcome after liver-kidney transplant for recurrent hemolytic uremic syndrome associated with a factor H mutation. Am J Transplant. 2006;6:1948–52.
  23. Scheiring J, Andreoli SP, Zimmerhackl LB. Treatment and outcome of Shiga-toxin- associated haemolytic uremic syndrome (HUS). Pediatr Nephrol 2008 ; 23 : 1749-60.
  24. Taylor M. Enterohaemorrhagic Escherichia coli and Shigella dyseteriae type 1-induced haemolytic uraemic syndrome. Pediatr Nephrol 2008 ; 23 : 1425-31.
  25. Weitz M, Amon O, Bassler D, Koenigsrainer A, Nadalin S. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome. Pediatr Nephrol. 2011;26:1325–9.
  26. Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V. for the French Study Group for aHUS/C3G. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol. 2012;8:643–657

Для продолжения работы требуется вход / регистрация